ZA200705427B - Heteroaromatic quinoline compounds and their use as PDE10 inhibitors - Google Patents

Heteroaromatic quinoline compounds and their use as PDE10 inhibitors

Info

Publication number
ZA200705427B
ZA200705427B ZA200705427A ZA200705427A ZA200705427B ZA 200705427 B ZA200705427 B ZA 200705427B ZA 200705427 A ZA200705427 A ZA 200705427A ZA 200705427 A ZA200705427 A ZA 200705427A ZA 200705427 B ZA200705427 B ZA 200705427B
Authority
ZA
South Africa
Prior art keywords
quinoline compounds
pde10 inhibitors
heteroaromatic quinoline
heteroaromatic
pde10
Prior art date
Application number
ZA200705427A
Other languages
English (en)
Inventor
Verhoest Patrick Robert
Hoover Dennis Jay
Helal Christopher John
Humphrey John Michael
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of ZA200705427B publication Critical patent/ZA200705427B/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/14—Quaternary ammonium compounds, e.g. edrophonium, choline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Reproductive Health (AREA)
  • Psychology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Gynecology & Obstetrics (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Hospice & Palliative Care (AREA)
  • Cardiology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pregnancy & Childbirth (AREA)
  • Vascular Medicine (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
ZA200705427A 2005-01-07 2007-07-03 Heteroaromatic quinoline compounds and their use as PDE10 inhibitors ZA200705427B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US64205805P 2005-01-07 2005-01-07

Publications (1)

Publication Number Publication Date
ZA200705427B true ZA200705427B (en) 2008-09-25

Family

ID=36589327

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA200705427A ZA200705427B (en) 2005-01-07 2007-07-03 Heteroaromatic quinoline compounds and their use as PDE10 inhibitors

Country Status (44)

Country Link
US (2) US7429665B2 (xx)
EP (1) EP1841757B1 (xx)
JP (1) JP4302762B2 (xx)
KR (1) KR100896380B1 (xx)
CN (2) CN101098866A (xx)
AP (1) AP2362A (xx)
AR (1) AR052863A1 (xx)
AT (1) ATE472543T1 (xx)
AU (1) AU2005323794B2 (xx)
BR (1) BRPI0518508A2 (xx)
CA (1) CA2592986C (xx)
CR (1) CR9180A (xx)
CU (1) CU23780B7 (xx)
CY (1) CY1110746T1 (xx)
DE (1) DE602005022115D1 (xx)
DK (1) DK1841757T3 (xx)
EA (1) EA012211B1 (xx)
EG (1) EG25993A (xx)
ES (1) ES2346674T3 (xx)
GE (1) GEP20094623B (xx)
GT (1) GT200600002A (xx)
HK (1) HK1167263A1 (xx)
HN (1) HN2006000668A (xx)
HR (1) HRP20100461T1 (xx)
IL (1) IL183851A (xx)
MA (1) MA29140B1 (xx)
ME (1) ME01142B (xx)
MX (1) MX2007008287A (xx)
MY (1) MY142052A (xx)
NL (1) NL1030863C2 (xx)
NO (1) NO340476B1 (xx)
NZ (1) NZ555737A (xx)
PE (1) PE20060873A1 (xx)
PL (1) PL1841757T3 (xx)
PT (1) PT1841757E (xx)
RS (1) RS51385B (xx)
SI (1) SI1841757T1 (xx)
SV (1) SV2008002365A (xx)
TN (1) TNSN07258A1 (xx)
TW (1) TWI312682B (xx)
UA (1) UA86283C2 (xx)
UY (1) UY29324A1 (xx)
WO (1) WO2006072828A2 (xx)
ZA (1) ZA200705427B (xx)

Families Citing this family (75)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2619462A1 (en) * 2005-08-16 2007-02-22 Amgen, Inc. Phosphodiesterase 10 inhibitors
AR056876A1 (es) * 2005-10-21 2007-10-31 Tanabe Seiyaku Co Compuestos de pirazolo[1-5-a]pirimidina, antagonistas de receptores canabinoides cb1, composiciones farmaceuticas que los contienen y usos en el tratamiento de enfermedades del sistema nervioso central, tales como trastornos psicoticos, neurologicos y similares
NL2000397C2 (nl) * 2006-01-05 2007-10-30 Pfizer Prod Inc Bicyclische heteroarylverbindingen als PDE10 inhibitoren.
EP2024353A2 (en) * 2006-03-16 2009-02-18 Pfizer Products Inc. Pyrazole compounds
US20090176829A1 (en) * 2006-05-02 2009-07-09 Pfizer Inc Bicyclic heteroaryl compounds as pde10 inhibitors
AR061793A1 (es) 2006-07-05 2008-09-24 Mitsubishi Tanabe Pharma Corp Compuesto de pirazolo[1,5-a] pirimidina y composicion farmaceutica
US20080090834A1 (en) * 2006-07-06 2008-04-17 Pfizer Inc Selective azole pde10a inhibitor compounds
US7786139B2 (en) * 2006-11-21 2010-08-31 Omeros Corporation PDE10 inhibitors and related compositions and methods
WO2008084299A1 (en) * 2006-12-21 2008-07-17 Pfizer Products Inc. Succinate salt of 2-((4-(1-methyl-4-(pyridin-4-yl)-1h-pyrazol-3-yl) phenoxy)methyl)quinoline
AP2010005167A0 (en) * 2007-08-01 2010-02-28 Pfizer Pyrazole compounds and their use as RAF inhibitors
RU2506260C2 (ru) * 2008-06-25 2014-02-10 Энвиво Фармасьютикалз, Инк. 1,2-дизамещенные гетероциклические соединения
EP2297133B1 (en) * 2008-06-25 2017-09-13 Forum Pharmaceuticals Inc. 1, 2 disubstituted heterocyclic compounds
ME02337B (me) 2009-02-05 2016-06-20 Takeda Pharmaceuticals Co Jedinjenja piridazinona
EP2400991A1 (en) 2009-02-24 2012-01-04 Janssen Pharmaceutica, N.V. Radiolabelled pde10 ligands
CN102369195B (zh) 2009-04-02 2014-04-16 默克专利有限公司 自分泌运动因子抑制剂
PT2427454E (pt) 2009-05-07 2013-06-20 Envivo Pharmaceuticals Inc Compostos fenoximetilo heterocíclicos
EP2308866A1 (de) * 2009-10-09 2011-04-13 Bayer CropScience AG Phenylpyri(mi)dinylpyrazole und ihre Verwendung als Fungizide
EP2493513B1 (en) * 2009-10-30 2014-07-30 Janssen Pharmaceutica NV Radiolabelled pde10 ligands
BR112012021198B1 (pt) * 2010-02-26 2021-12-14 Mitsubishi Tanabe Pharma Corporation Compostos de pirazolopirimidina, composições relacionadas e seu uso como inibidores de pde10
CN107445919A (zh) 2010-03-12 2017-12-08 奥默罗斯公司 Pde10抑制剂以及相关组合物和方法
US8969349B2 (en) * 2010-05-26 2015-03-03 Sunovion Pharmaceuticals Inc. Substituted quinoxalines and quinoxalinones as PDE-10 inhibitors
MY165585A (en) 2010-06-24 2018-04-05 Takeda Pharmaceuticals Co Fused heterocyclic compounds as phosphodiesterases (pdes) inhibitors
JP5760085B2 (ja) 2010-08-04 2015-08-05 武田薬品工業株式会社 縮合複素環化合物
WO2012018058A1 (ja) 2010-08-04 2012-02-09 武田薬品工業株式会社 縮合複素環化合物
EP2604597B1 (en) 2010-08-10 2017-01-04 Takeda Pharmaceutical Company Limited Heterocyclic compound and use thereof inhibitor of phosphodiesterase 10a
JP2014510055A (ja) 2011-02-18 2014-04-24 アラーガン インコーポレイテッド ホスホジエステラーゼ１０（ｐｄｅ１０ａ）阻害剤としての置換６，７−ジアルコキシ−３−イソキノリノール誘導体
US20120214842A1 (en) 2011-02-18 2012-08-23 Exonhit Therapeutics Sa Methods for treating diseases of the retina
AU2012221828C1 (en) 2011-02-23 2015-10-01 Pfizer Inc. Imidazo[5,1-f][1,2,4]triazines for treatment of neurological disorders
MX355309B (es) 2011-03-14 2018-04-16 Boehringer Ingelheim Int Inhibidores de benzodioxano de la produccion de leucotrieno.
WO2012124782A1 (ja) 2011-03-16 2012-09-20 武田薬品工業株式会社 縮合複素環化合物
JP2014122161A (ja) * 2011-03-31 2014-07-03 Astellas Pharma Inc ピラゾール化合物
SG195085A1 (en) 2011-06-07 2013-12-30 Pfizer Pyrazolo[3,4-d]pyrimidine compounds and their use as pde2 inhibitors and/or cyp3a4 inhibitors
EP2734516B1 (en) 2011-07-19 2015-06-17 Boehringer Ingelheim International GmbH Arylpyrazole ethers as inhibitors of leukotriene a4 hydrolase
JP6054869B2 (ja) 2011-07-29 2016-12-27 武田薬品工業株式会社 複素環化合物
BR112014004310B8 (pt) 2011-08-25 2023-04-18 Merck Sharp & Dohme Composto de pirimidina inibidor da enzima fosfodiesterase 10, composição farmacêutica, uso de um composto
WO2013045607A1 (en) * 2011-09-30 2013-04-04 H. Lundbeck A/S Quinazoline linked heteroaromatic tricycle derivatives as pde10a enzyme inhibitors
CN103159738B (zh) * 2011-12-19 2016-09-07 上海泓博智源医药股份有限公司 炔基桥连的杂芳香化合物及其应用
US9138494B2 (en) * 2011-12-23 2015-09-22 Abbvie Inc. Radiolabeled PDE10A ligands
CA2866471A1 (en) 2012-03-06 2013-09-12 Boehringer Ingelheim International Gmbh Benzodioxanes in combination with other actives for inhibiting leukotriene production
US8946203B2 (en) 2012-03-06 2015-02-03 Boehringer Ingelheim International Gmbh Benzodioxane inhibitors of leukotriene production
EP2841070B1 (en) * 2012-04-24 2018-07-25 Board Of Trustees Of Northern Illinois University Design and synthesis of novel inhibitors of isoprenoid biosynthesis
TW201416354A (zh) 2012-07-17 2014-05-01 Boehringer Ingelheim Int 白三烯生成抑制劑
WO2014071044A1 (en) 2012-11-01 2014-05-08 Allergan, Inc. Substituted 6,7-dialkoxy-3-isoquinoline derivatives as inhibitors of phosphodiesterase 10 (pde10a)
US9790203B2 (en) 2012-11-26 2017-10-17 Abbvie Inc. Inhibitor compounds of phosphodiesterase type 10A
ES2723876T3 (es) 2013-02-27 2019-09-03 Mochida Pharm Co Ltd Nuevos derivados de pirazol
AU2014230745A1 (en) 2013-03-14 2015-09-03 AbbVie Deutschland GmbH & Co. KG Novel inhibitor compounds of phosphodiesterase type 10A
JPWO2014142322A1 (ja) 2013-03-15 2017-02-16 第一三共株式会社 ベンゾチオフェン誘導体
US10039764B2 (en) * 2013-07-12 2018-08-07 University Of South Alabama Treatment and diagnosis of cancer and precancerous conditions using PDE10A inhibitors and methods to measure PDE10A expression
US9303018B2 (en) 2013-07-15 2016-04-05 Boehringer Ingelheim International Gmbh Inhibitors of leukotriene production
EP3022194B1 (en) 2013-07-15 2017-05-17 Boehringer Ingelheim International GmbH Inhibitors of leukotriene production
US9200016B2 (en) 2013-12-05 2015-12-01 Allergan, Inc. Substituted 6, 7-dialkoxy-3-isoquinoline derivatives as inhibitors of phosphodiesterase 10 (PDE 10A)
CA2931189C (en) 2013-12-13 2017-09-26 F. Hoffmann-La Roche Ag Inhibitors of bruton's tyrosine kinase
NZ630810A (en) 2014-04-28 2016-03-31 Omeros Corp Processes and intermediates for the preparation of a pde10 inhibitor
NZ630803A (en) 2014-04-28 2016-03-31 Omeros Corp Optically active pde10 inhibitor
BR112017022936A2 (pt) 2015-04-24 2018-07-17 Omeros Corp inibidores da pde10 e composições e métodos relacionados
JP2018535969A (ja) 2015-11-04 2018-12-06 オメロス コーポレーション Ｐｄｅ１０阻害剤の固体状態形態
US20210379061A1 (en) 2018-09-28 2021-12-09 Takeda Pharmaceutical Company Limited Balipodect for treating or preventing autism spectrum disorders
WO2020094591A1 (en) 2018-11-06 2020-05-14 H. Lundbeck A/S Pde10a inhibitors for treating negative symptoms and cognitive impairments in a patient suffering from schizophrenia
CN109627232B (zh) * 2018-11-19 2021-02-09 广东环境保护工程职业学院 一种喹啉类化合物及其制备方法和应用
CN109384766B (zh) * 2018-11-19 2021-02-09 广东环境保护工程职业学院 一种喹啉类化合物及其制备方法和应用
CA3121202A1 (en) 2018-11-30 2020-06-04 Nuvation Bio Inc. Pyrrole and pyrazole compounds and methods of use thereof
JP2022517316A (ja) 2019-01-11 2022-03-08 ネイジス ファーマシューティカルズ インコーポレイテッド ロイコトリエン合成阻害剤
GB202002926D0 (en) 2020-02-28 2020-04-15 Benevolentai Tech Limited Compositions and uses thereof
WO2021257857A1 (en) 2020-06-19 2021-12-23 Incyte Corporation Naphthyridinone compounds as jak2 v617f inhibitors
US11753413B2 (en) 2020-06-19 2023-09-12 Incyte Corporation Substituted pyrrolo[2,1-f][1,2,4]triazine compounds as JAK2 V617F inhibitors
AU2021300429A1 (en) 2020-07-02 2023-02-16 Incyte Corporation Tricyclic urea compounds as JAK2 V617F inhibitors
WO2022006456A1 (en) 2020-07-02 2022-01-06 Incyte Corporation Tricyclic pyridone compounds as jak2 v617f inhibitors
US11661422B2 (en) 2020-08-27 2023-05-30 Incyte Corporation Tricyclic urea compounds as JAK2 V617F inhibitors
WO2022140231A1 (en) 2020-12-21 2022-06-30 Incyte Corporation Deazaguaine compounds as jak2 v617f inhibitors
EP4298099A1 (en) 2021-02-25 2024-01-03 Incyte Corporation Spirocyclic lactams as jak2 v617f inhibitors
GB202110990D0 (en) * 2021-07-30 2021-09-15 Benevolentai Cambridge Ltd Organic compound and their uses
AU2022376563A1 (en) 2021-11-01 2023-12-07 Alkahest, Inc. Benzodioxane modulators of leukotriene a4 hydrolase (lta4h) for prevention and treatment of aging-associated diseases
CN113956436B (zh) * 2021-11-09 2023-05-30 万华化学（宁波）有限公司 一种浅色且存储过程中色号稳定的二苯基甲烷二异氰酸酯组合物
TW202337453A (zh) 2022-03-17 2023-10-01 美商英塞特公司 作為ｊａｋ２ ｖ６１７ｆ抑制劑之三環脲化合物
CN116731017B (zh) * 2023-06-02 2024-10-01 海南大学 一种喹啉并哌啶类化合物及其制备方法与应用

Family Cites Families (59)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA962021A (en) * 1970-05-21 1975-02-04 Robert W. Gore Porous products and process therefor
US4340480A (en) * 1978-05-15 1982-07-20 Pall Corporation Process for preparing liquophilic polyamide membrane filter media and product
US4876346A (en) * 1985-05-02 1989-10-24 American Home Products Corporation Quinoline compounds
US4681940A (en) * 1985-11-19 1987-07-21 American Home Products Corporation 5-[3-[[2-quinolyl]methoxy]phenyl]-1,3-oxazoles
US5627079A (en) * 1989-03-27 1997-05-06 The Research Foundation Of State University Of New York Refunctionalized oxyfluorinated surfaces
US5270193A (en) * 1989-10-27 1993-12-14 E. I. Dupont De Nemours And Company Immobilization of biomolecules on perfluorocarbon surfaces
EP0456939B1 (en) * 1990-05-18 1995-02-22 Japan Gore-Tex, Inc. Hydrophilic porous fluoropolymer membrane
PT100905A (pt) * 1991-09-30 1994-02-28 Eisai Co Ltd Compostos heterociclicos azotados biciclicos contendo aneis de benzeno, ciclo-hexano ou piridina e de pirimidina, piridina ou imidazol substituidos e composicoes farmaceuticas que os contem
GB9202633D0 (en) * 1992-02-07 1992-03-25 Fujisawa Pharmaceutical Co Heterocyclic derivatives
ATE264323T1 (de) * 1992-09-14 2004-04-15 Takeda Chemical Industries Ltd Heterocyclische verbindungen und ihre verwendung als angiotensin ii antagonisten
DE4238389A1 (de) * 1992-11-13 1994-05-19 Bayer Ag Verfahren zur Durchführung immundiagnostischer Nachweise
US5614099A (en) * 1994-12-22 1997-03-25 Nitto Denko Corporation Highly permeable composite reverse osmosis membrane, method of producing the same, and method of using the same
US6207369B1 (en) * 1995-03-10 2001-03-27 Meso Scale Technologies, Llc Multi-array, multi-specific electrochemiluminescence testing
US5843789A (en) * 1995-05-16 1998-12-01 Neomecs Incorporated Method of analysis of genomic biopolymer and porous materials for genomic analyses
AU6854696A (en) * 1995-09-22 1997-04-09 Gore Hybrid Technologies, Inc. Improved cell encapsulation device
US5914182A (en) * 1996-06-03 1999-06-22 Gore Hybrid Technologies, Inc. Materials and methods for the immobilization of bioactive species onto polymeric substrates
US5843958A (en) * 1996-11-27 1998-12-01 Ortho Pharmaceutical Corporation Arylpyrazoles as leukotriene inhibitors
US6342292B1 (en) * 1997-12-16 2002-01-29 Asahi Kasei Kabushiki Kaisha Organic thin film and process for producing the same
US6451396B1 (en) * 1998-02-13 2002-09-17 Gore Enterprise Holdings, Inc. Flexure endurant composite elastomer compositions
US6780582B1 (en) * 1998-07-14 2004-08-24 Zyomyx, Inc. Arrays of protein-capture agents and methods of use thereof
US6994972B2 (en) * 1999-09-02 2006-02-07 Corning Incorporated Porous substrates for DNA arrays
US6750023B2 (en) * 1999-09-02 2004-06-15 Corning Incorporated Porous inorganic substrate for high-density arrays
US6790613B1 (en) * 1999-11-12 2004-09-14 Amersham Biosciences Ab Method of preparing an oligonucleotide array
JP2001226650A (ja) * 2000-02-16 2001-08-21 Nitto Denko Corp 放射線硬化型熱剥離性粘着シート、及びこれを用いた切断片の製造方法
US20030219816A1 (en) * 2001-07-02 2003-11-27 Keith Solomon Composite microarray slides
AU780441B2 (en) * 2000-07-05 2005-03-24 3M Innovative Properties Company Improved low fluorescence nylon/glass composites for micro-analytical diagnostic applications
JP2004502949A (ja) * 2000-07-06 2004-01-29 キュノ、インコーポレーテッド 微量分析診断用途のための微細多孔膜と固体支持体との改良された結合体
TW513485B (en) * 2000-07-10 2002-12-11 Ind Tech Res Inst On-spot hydrophilic enhanced slide and preparation thereof
US6977155B2 (en) * 2000-08-10 2005-12-20 Corning Incorporated Arrays of biological membranes and methods and use thereof
EP1184349A1 (en) * 2000-09-01 2002-03-06 A.S.B.L. Facultes Universitaires Notre-Dame De La Paix Method for obtaining a surface activation of a solid support for building biochips microarrays
JP2002153272A (ja) * 2000-11-24 2002-05-28 Inst Of Physical & Chemical Res 生体分子マイクロアレイ
US7250518B2 (en) * 2001-01-31 2007-07-31 Pfizer Inc. Nicotinamide acids, amides, and their mimetics active as inhibitors of PDE4 isozymes
US20030032579A1 (en) * 2001-04-20 2003-02-13 Pfizer Inc. Therapeutic use of selective PDE10 inhibitors
DE10130151A1 (de) * 2001-06-22 2003-01-02 Bayer Ag Neue Verwendung für PDE 10A-Inhibitoren
US6844028B2 (en) * 2001-06-26 2005-01-18 Accelr8 Technology Corporation Functional surface coating
US7054862B2 (en) * 2001-06-29 2006-05-30 International Business Machines Corporation Method and system for long-term update and edit control in a database system
FR2826957B1 (fr) * 2001-07-09 2005-09-30 Centre Nat Rech Scient Procede de fonctionnalisation de supports solides, supports solides fonctionnalises et leurs utilisations
WO2003014115A1 (en) 2001-08-06 2003-02-20 Bayer Aktiengesellschaft 3-substituted pyrrolo (2.1-a) isoquinoline derivatives
US20030068621A1 (en) * 2001-10-04 2003-04-10 Jonathan Briggs Method and device for producing oligonucleotide arrays
JP3884995B2 (ja) * 2002-05-29 2007-02-21 日東電工株式会社 皮膚貼着用粘着シート
US7332273B2 (en) * 2002-06-20 2008-02-19 Affymetrix, Inc. Antireflective coatings for high-resolution photolithographic synthesis of DNA arrays
AU2003244080A1 (en) * 2002-06-26 2004-01-19 Kyowa Hakko Kogyo Co., Ltd. Phosphodiesterase inhibitor
JP2004072743A (ja) * 2002-08-05 2004-03-04 Oce Technol Bv 印刷システムにおける色の表現方法
US20030036085A1 (en) * 2002-08-19 2003-02-20 Salinaro Richard F Membranes
US20040043508A1 (en) * 2002-09-03 2004-03-04 Frutos Anthony G. Polymer-coated substrates for binding biological molecules
US20040081886A1 (en) * 2002-10-25 2004-04-29 David Zuckerbrod Separator for electrochemical devices
US20040137608A1 (en) * 2002-11-27 2004-07-15 Aaron Garzon Chemical microarrays and method for constructing same
KR100994566B1 (ko) * 2003-01-20 2010-11-15 삼성전자주식회사 고정화 영역을 갖는 포토레지스트 막을 포함하는 어레이장치 및 이를 이용한 표적 물질 검출방법
US20040152081A1 (en) * 2003-01-31 2004-08-05 Leproust Eric M. Viscosity control during polynucleotide synthesis
JP4098159B2 (ja) * 2003-05-28 2008-06-11 オリンパス株式会社 アクチュエータ駆動装置
MXPA05013132A (es) 2003-06-03 2006-05-25 Rib X Pharmaceuticals Inc Compuestos heterociclicos de biarilo y metodos de produccion y su uso.
US20050064431A1 (en) * 2003-09-09 2005-03-24 Eastman Kodak Company Biological microarray comprising polymer particles and method of use
US20050079506A1 (en) * 2003-10-09 2005-04-14 Eastman Kodak Company Filled, biological microarray and method for use
US20050095602A1 (en) * 2003-11-04 2005-05-05 West Jason A. Microfluidic integrated microarrays for biological detection
WO2005044142A2 (en) * 2003-11-10 2005-05-19 Angiotech International Ag Intravascular devices and fibrosis-inducing agents
US20060024347A1 (en) * 2004-02-10 2006-02-02 Biosurface Engineering Technologies, Inc. Bioactive peptide coatings
US7323347B2 (en) * 2004-05-27 2008-01-29 Sensata Technologies, Inc. Biosensor surface structures and methods
WO2005120514A1 (en) * 2004-06-07 2005-12-22 Pfizer Products Inc. Phosphodiesterase 10 inhibition as treatment for obesity-related and metabolic syndrome-related conditions
KR101159071B1 (ko) * 2005-01-14 2012-06-26 삼성전자주식회사 신규한 히드로겔 공중합체, 상기 공중합체가 코팅되어있는 기판, 상기 공중합체를 이용하여 마이크로어레이를제조하는 방법 및 그에 의하여 제조된 마이크로어레이

Also Published As

Publication number Publication date
IL183851A (en) 2012-03-29
PT1841757E (pt) 2010-08-31
DE602005022115D1 (de) 2010-08-12
UY29324A1 (es) 2006-08-31
ES2346674T3 (es) 2010-10-19
CN101098866A (zh) 2008-01-02
NO340476B1 (no) 2017-05-02
US7429665B2 (en) 2008-09-30
UA86283C2 (uk) 2009-04-10
BRPI0518508A2 (pt) 2008-11-25
GEP20094623B (en) 2009-02-25
CN102491969B (zh) 2015-08-19
EA012211B1 (ru) 2009-08-28
CA2592986A1 (en) 2006-07-13
CN102491969A (zh) 2012-06-13
NL1030863A1 (nl) 2006-07-10
DK1841757T3 (da) 2010-09-13
TWI312682B (en) 2009-08-01
CA2592986C (en) 2011-02-15
ATE472543T1 (de) 2010-07-15
CU20070156A7 (es) 2009-03-16
JP2008526825A (ja) 2008-07-24
IL183851A0 (en) 2007-10-31
EP1841757B1 (en) 2010-06-30
US20080214607A1 (en) 2008-09-04
WO2006072828A2 (en) 2006-07-13
TNSN07258A1 (fr) 2008-12-31
KR20070091005A (ko) 2007-09-06
US7825254B2 (en) 2010-11-02
CR9180A (es) 2007-07-04
ME01142B (me) 2013-03-20
JP4302762B2 (ja) 2009-07-29
MA29140B1 (fr) 2008-01-02
EP1841757A2 (en) 2007-10-10
CU23780B7 (es) 2012-02-15
MX2007008287A (es) 2007-09-07
PL1841757T3 (pl) 2010-10-29
AP2362A (en) 2012-02-08
HRP20100461T1 (hr) 2010-11-30
PE20060873A1 (es) 2006-09-04
NO20072918L (no) 2007-07-05
EG25993A (en) 2012-11-28
RS51385B (en) 2011-02-28
GT200600002A (es) 2006-08-01
TW200637555A (en) 2006-11-01
HN2006000668A (es) 2010-09-17
NZ555737A (en) 2010-01-29
CY1110746T1 (el) 2015-06-10
NL1030863C2 (nl) 2006-12-28
EA200701252A1 (ru) 2007-12-28
US20060154931A1 (en) 2006-07-13
SV2008002365A (es) 2008-02-08
AR052863A1 (es) 2007-04-11
AU2005323794A1 (en) 2006-07-13
MY142052A (en) 2010-08-30
HK1167263A1 (zh) 2012-11-23
WO2006072828A3 (en) 2006-11-09
SI1841757T1 (sl) 2010-09-30
KR100896380B1 (ko) 2009-05-08
AP2007004043A0 (en) 2007-06-30
AU2005323794B2 (en) 2012-07-19

Similar Documents

Publication Publication Date Title
EG25993A (en) Heteroaromatic quinoline compounds and their use as pde10 inhibitors
HUS2200052I1 (hu) Imidazotriazinok és imidazopirimidinek mint kinázgátlók
ZA200801822B (en) Pyrazine derivatives and use as p13k inhibitors
AP2006003694A0 (en) Quinoline derivatives and use thereof as mycobacterial inhibitors
HK1114380A1 (en) Pyrrolopyrazoles as kinase inhibitors
ZA200606070B (en) Substituted quinolines and their use as mycrobacterial inhibitors
IL225653A0 (en) Homo- and hetero-cyclic compounds suitable as cetp inhibitors
HK1137756A1 (en) Substituted dihydropyrazolones and use thereof as hif-prolyl-4 -hydroxylase inhibitors hif--4-
ZA200708868B (en) 7-Amino alkylidenyl-heterocyclic quinolones and napthyridones